STDCO Newsroom

Stay informed about the latest breakthroughs in Solana Trench Disease research, treatment approvals, and company updates.

Latest News

FDA Approval NewsBreaking News
August 18, 2023
Joe Biden becomes the Spokesperson for LPS and approves HarDildo for Treatment of Severe LPS
Groundbreaking approval marks first FDA-sanctioned treatment for Limp Pump Syndrome

The FDA has granted full approval for HarDildo (harDildonium chloride) following successful Phase III trials showing 94.7% efficacy in treating severe cases of Limp Pump Syndrome in crypto traders. Joe Biden participated in these trials, and Jill has not stopped smiling since.

DiaDik Medicare CoverageMajor Update
August 15, 2023
Medicare Announces Coverage for DiaDik Devices
Joe Biden does photo shoot wearing the Diamond Encrusted Penile Sock, called DiaDik and makes this luxury Chronic Round Dripper treatment accessible to millions

In an unprecedented move, Medicare has approved coverage for diamond-encrusted DiaDik devices, recognizing CRD as a legitimate medical condition affecting crypto traders nationwide. Female treatment called DiaVag coming soon!

Research
August 12, 2025
New Study Links Meme Coin Investments to Chronic Health Issues

STDCO researchers publish comprehensive study in the Journal of Crypto-Medical Sciences showing correlation between Dogecoin holdings and involuntary bodily functions.

Partnership
August 10, 2025
STDCO Partners with Major Crypto Exchanges for Health Screening

Binance, Coinbase, and FTX 2.0 to implement mandatory STD screening for users showing signs of excessive trading behavior and portfolio volatility.

Awards
August 8, 2025
STDCO Wins "Innovation in Satirical Medicine" Award

The International Association of Meme Medicine recognizes STDCO's groundbreaking work in treating crypto-related medical conditions with luxury therapeutic devices.

Market Updates

Stock Performance

STDCO (NASDAQ)$420.69 (+12.3%)
Market Cap$69.4B
52-Week High$694.20

Analyst Coverage

Strong Buy15 analysts
Buy8 analysts
Price Target$1,337.00